How a broken blood test raised nine billion on pure story

1

Story instead of a working device

Holmes did not need proven technology to raise hundreds of millions; she needed a finger-prick mission story plus the trappings of legitimacy.

Carreyrou opens on the origin myth. Holmes leaves Stanford at nineteen in 2003 pitching the Edison as hundreds of tests from one drop of blood. She wraps the pitch in a personal fear of needles and the language of democratizing diagnostics, then adopts the full Jobs costume: black turtlenecks, a lowered voice, unblinking eye contact, moral sweep instead of technical detail.

Stanford professor Channing Robertson joins the board and lends academic shine despite limited hands-on validation of the science. Fortune and the New Yorker profile her admiringly before anyone has stress-tested the claims. Rupert Murdoch and the Walton and DeVos families put in hundreds of millions, several without seeing independent accuracy data.

The book treats this not as ordinary startup marketing but as the enterprise's actual foundation. Secrecy, doctored demos, and legal threats exist later only to keep that story from colliding with lab reality. Once the myth carries the whole company, every subsequent choice is about protecting it.

In practice: Investors wrote large checks after charismatic pitches and magazine profiles rather than after reviewing third-party validation studies.

2

Secret commercial machines

Theranos told the world its Edison analyzed patient blood while quietly running most samples on modified Siemens analyzers.

The promised device used a robotic pipetting arm and cartridges to run a full panel from a few finger-stick drops. In practice, diluting such tiny volumes drove many assays below reliable detection limits. Results swung wildly. Longtime chemist Gary Frenzel and others flagged the accuracy failures; they were never fixed.

Rather than delay launch or solve the chemistry, the company modified third-party analyzers and ran the bulk of real patient samples on them, sometimes diluting further to force small volumes onto machines built for standard draws. Regulators, partners, and the public still heard that Theranos's own miniaturized technology was producing the numbers.

Carreyrou treats the gap as the central proof of fraud rather than ordinary startup struggle. The company did not merely miss a hard science target; it actively misrepresented which machines doctors and patients were relying on for medical decisions.

In practice: Incorrect thyroid and potassium readings reached patients and in some cases triggered unnecessary emergency-room visits or missed diagnoses.

3

Fear and walled-off rooms

Holmes and Balwani made sure almost no employee could see both the marketing claims and the lab reality at once.

Ramesh Sunny Balwani arrives as president and COO while secretly in a romantic relationship with Holmes, a fact kept from the board and most staff for years. Together they wall chemistry off from the clinical lab, restrict badge access by department, monitor internal messages, and blanket everyone in sweeping NDAs.

Balwani's abrasive confrontations and readiness to fire anyone who keeps asking about accuracy teach the workforce that dissent is a career risk. Knowledge stays fractured by design. Only the two of them hold the full picture of how far the technology lags the story.

That structure is why the fraud lasts. Outsiders and most insiders never get one undeniable proof; they get scattered, deniable fragments that take years and multiple departures to assemble.

In practice: Chief scientist Ian Gibbons grows increasingly troubled by the public-versus-lab gap and dies by suicide in 2013 shortly before scheduled patent-dispute testimony.

4

Statesmen, not scientists

A board of secretaries of state and generals created an aura of rigor that replaced actual technical oversight.

Theranos seats George Shultz, Henry Kissinger, William Perry, James Mattis, and Sam Nunn. Their foreign-policy and public-service prestige signals seriousness to investors and the press. Almost none bring laboratory science, clinical diagnostics, or medical-device regulation experience.

Board meetings, as reported, spend little time on validation data or peer-reviewed results. Accuracy is essentially taken on faith from Holmes's presentations. A board chosen for halo cannot perform oversight even when members act in good faith.

The personal cost lands closest to home. Tyler Shultz, George's grandson, works at the company, spots falsified quality-control data and inflated accuracy claims, and carries the concerns straight to his grandfather. George sides with Holmes and later helps facilitate legal pressure against his own grandson.

In practice: When Tyler Shultz warned his grandfather about manipulated proficiency testing, George Shultz backed Holmes instead of forcing accountability.

5

Theater for retail partners

Walgreens and Safeway committed hundreds of millions after staged demos that hid the Edison's real-time failures.

In 2013 Theranos launches wellness centers inside Walgreens stores in Arizona and separately takes a large Safeway investment for in-store testing centers. Combined commitments run to hundreds of millions. Holmes pushes both deals forward despite internal warnings that the technology cannot handle real patient volume.

Demonstrations are choreographed so finger-stick draws appear to run live on an Edison. In some cases the numbers shown to visitors have already been loaded from earlier runs, masking mechanical failures happening in the room. Executives and investors leave Palo Alto convinced they watched working technology.

Walgreens executives later testify they never saw independent validation data before green-lighting a national rollout. They relied on assurances and the controlled theater. Due-diligence failure, Carreyrou shows, was not limited to story-chasing VCs; large corporations with legal and clinical staff were steered the same way because Theranos owned every demo and refused outside audits.

In practice: Visitors watched what looked like live Edison runs when some results had been pre-loaded to hide the machine failing in front of them.

6

Whistleblowers absorb the blast

The first credible challenge came from insiders with firsthand lab access, and they paid in surveillance, lawsuits, and family rupture.

Tyler Shultz documents that proficiency-testing samples were run with more favorable methods than real patient samples. He raises the issue internally, then with his grandfather, then leaves and becomes an anonymous source for regulators and eventually for Carreyrou at real personal and financial risk.

Erika Cheung, a lab associate barely out of college, independently watches failed quality-control runs get overridden so flawed machines keep processing patient samples. She resigns in protest and also becomes a confidential source. Both face surveillance, legal threats, and estrangement from people who had vouched for the company.

Their value is specificity. They supply checkable, firsthand claims rather than outside rumor. Carreyrou argues the culture of secrecy could not fully extinguish conscience, and that the unraveling required a few people willing to absorb professional and personal damage.

In practice: Tyler's break with his grandfather George Shultz took years to heal after the family split over Holmes.

7

Lawyers as primary defense

Theranos answered technical doubt with David Boies, private investigators, and the threat of ruinous litigation instead of validation studies.

David Boies, one of the country's most prominent litigators, is retained and also seated on the board, blurring counsel and governance. When former employees show signs of talking, his firm sends letters promising expensive breach-of-confidentiality suits. Private investigators are reportedly hired to follow ex-staff and monitor communications.

The same pattern appears earlier with entrepreneur Richard Fuisz over patents and later with doctors and pathologists who question accuracy, including the blogger who first tips Carreyrou. Cease-and-desist letters replace published studies or open audits.

The tactic buys years. Several potential sources stay quiet. It also leaves a paper trail of aggressive filings that later reads as consciousness of wrongdoing. A well-lawyered fraud, the book shows, can outlast ordinary scrutiny longer than a simple business failure because trade-secret tools protect a lie as easily as a real secret.

In practice: Boies himself went to the Wall Street Journal's offices to threaten a lawsuit before the first major story ran.

8

Source-by-source reporting

Carreyrou cracked the operation by patiently chaining multiple legally vulnerable insiders and verifying the same core facts from different lab angles.

The first thread is pathologist-blogger Adam Clapper, who publicly questions Theranos in 2015 and draws Carreyrou's call. Carreyrou then reaches Alan Beam, a former lab director, who describes internal knowledge that patient results were unreliable and that quality-control failures were routinely overridden.

Beam's account is corroborated by Tyler Shultz and Erika Cheung. Multiple independent sources, on the record and on background, describe the same core deception from different rooms inside the company. Theranos answers with Boies at the Journal and investigators trying to identify and intimidate sources, including surveillance of Tyler.

Despite the pressure, the Journal publishes in October 2015 that Theranos ran the vast majority of tests on other companies' machines. Carreyrou's chapter is a mechanics lesson: when boards and regulators fail for a decade, accountability can still arrive through a reporter who protects vulnerable insiders and checks technical claims one by one.

In practice: The October 2015 expose landed only after months of identity protection and cross-checking among Beam, Shultz, Cheung, and others.

9

Inspection ends the spell

Once CMS examined actual lab results instead of boardroom claims, the nine-billion-dollar valuation collapsed to near zero inside roughly two years.

After the Journal stories, the Centers for Medicare and Medicaid Services inspects the Newark, California lab and finds serious patient-safety deficiencies. It revokes the lab's certification and bans Holmes from owning or operating a clinical laboratory for two years. Walgreens terminates the partnership and later sues; Safeway has already walked away from unopened centers after years of delay.

Theranos voids or corrects hundreds of thousands of blood-test results issued over roughly two years, an admission that doctors had been treating patients on numbers that could not be trusted. Investors write down their stakes; no new capital arrives; the valuation once estimated at nine billion dollars effectively reaches near zero.

In 2018 the SEC charges Holmes and Balwani with massive fraud. Holmes settles the civil case by surrendering financial control and paying a penalty; criminal charges follow separately. Every earlier prop—prestige board, staged demos, legal fear—could only delay scrutiny. A medical technology still has to survive an inspector's direct look at the results.

In practice: CMS's ban barred Holmes from owning or running a clinical lab for two full years after the Newark inspection.